BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28

• 

  Business

  BioNTech and Medigene Link Up for Solid Tumor T-Cell Treatments

  BioNTech and Medigene announced a global agreement to develop T-cell immunotherapies against cancer. The three-year collaboration will focus on multiple solid tumor targets.

  February 22, 2022

   · 

  3 min read

   · 

  Hannah Chudleigh
• 

  Pharm Country

  Laser Effectively Controls Antigens for 10 Neurodegenerative Diseases in the Lab

  Halberd has demonstrated it can control each of the top 10 antigens associated with various neurodegenerative diseases, including Alzheimer’s, Parkinson’s, epilepsy, TBI and PTSD.

  February 22, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  Ophthalmology Biotech Sees Series A Hit $65M

  Proceeds will be used to assemble and develop a diversified pipeline of therapies to address sight-threatening illnesses.

  February 22, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Drug Development

  Gerngross Hits Exit Button as Adagio Prepares for Potential EUA Bid

  Weeks after announcing that its lead monoclonal antibody was demonstrating efficacy against the Omicron variant, Adagio Therapeutics CEO Tillman Gerngross steps down.

  February 22, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Deals

  In Hale and Good Health, GSK Announces Haleon

  GlaxoSmithKline unveiled plans for its new spinout in the consumer health division, Haleon. It is expected to be in place by mid-2022.

  February 22, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  Takeda Teams Up with Code in $2B Rare Disease Pact

  The companies will design and develop targeted gene therapies for a liver-directed rare disease program and conduct additional studies for central nervous system-directed rare disease programs.

  February 22, 2022

   · 

  3 min read

   · 

  Hayley Shasteen
• 

  Policy

  Five Confounding COVID Questions

  The COVID-19 pandemic and the virus that causes it, SARS-CoV-2, has been resilient, unpredictable and confounding from the very beginning.

  February 22, 2022

   · 

  6 min read

   · 

  Mark Terry
• 

  Drug Development

  Synairgen Crashes as Inhaled COVID-19 Treatment Fails in Phase III

  Synairgen watched its stock plummet 85% after reporting disappointing Phase III results for its inhaled COVID-19 treatment on Feb. 21.

  February 22, 2022

   · 

  2 min read

   · 

  Kate Goodwin
• 

  Drug Development

  4D Gets Green Light to Test First Live Biotherapeutic for Parkinson’s

  With IND approval, the therapeutics have become the first LBPs for Parkinson’s disease cleared by the FDA.

  February 22, 2022

   · 

  3 min read

   · 

  Hayley Shasteen
• 

  Drug Development

  Mallinckrodt Kidney Drug Derailed Again by FDA CRL

  A new packaging and labeling manufacturing facility has derailed the potential approval of Malinckrodt’s investigational hepatorenal syndrome (HRS) treatment, terlipressin.

  February 22, 2022

   · 

  2 min read

   · 

  Alex Keown